48
Participants
Start Date
October 31, 2006
Primary Completion Date
September 30, 2012
Study Completion Date
May 31, 2014
Allogeneic Pancreatic Islet Cells
200 ml suspension of allogenic human purified islets
Antithymocyte Globulin
Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
Sirolimus
Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
Tacrolimus
On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
Etanercept
Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
Islet Transplantation
Transplantation of pancreatic islet cell
Basiliximab
Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
University of Pennsylvania, Philadelphia
Emory University, Atlanta
University of Miami, Miami
University of Minnesota, Minneapolis
Northwestern University, Chicago
University of Illinois, Chicago, Chicago
University of Callifornia, San Francisco, San Francisco
University of Alberta, Edmonton
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
National Institute of Allergy and Infectious Diseases (NIAID)
NIH